What is MS Phase III Arbaclofen Study?

Category: Others

false

There are two MS Phase III Arbaclofen Studies: One is a dose escalation study to examine the safety and efficacy of Arbaclofen in MS patients with spasticity. NCT01844232 The other study is looking at the long term safety and efficacy of Arbaclofen in MS. NCT01360489

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
0
Mild
0
None
1

Commonly reported side effects and conditions associated with MS Phase III Arbaclofen Study

Side effect Patients

Why patients stopped taking MS Phase III Arbaclofen Study

Multiple reasons could be selected

Reason Patients
Course of treatment ended 1
See 1 patient who's stopped using MS Phase III Arbaclofen Study

Duration

Stopped using MS Phase III Arbaclofen Study

Duration Patients
1 - 2 years 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:
There are no evaluations for MS Phase III Arbaclofen Study.